Literature DB >> 10428500

Cell biology of the osteoclast.

G D Roodman1.   

Abstract

The osteoclast is a hematopoietic cell derived from CFU-GM and branches from the monocyte-macrophage lineage early during the differentiation process. The marrow microenvironment appears critical for osteoclast formation due to production of RANK ligand, a recently described osteoclast differentiation factor, by marrow stromal cells in response to a variety of osteotropic factors. In addition, factors such as osteoprotegerin, a newly described inhibitor of osteoclast formation, as well as secretory products produced by the osteoclast itself and other cells in the marrow enhance or inhibit osteoclast formation. The identification of the role of oncogenes such as c-fos and pp60 c-src in osteoclast differentiation and bone resorption have provided important insights in the regulation of normal osteoclast activity. Current research is beginning to delineate the signaling pathways involved in osteoclastic bone resorption and osteoclast formation in response to cytokines and hormones. The recent development of osteoclast cell lines may make it possible for major advances to our understanding of the biology of the osteoclast to be realized in the near future.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428500     DOI: 10.1016/s0301-472x(99)00061-2

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  120 in total

1.  IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.

Authors:  A C Bendixen; N K Shevde; K M Dienger; T M Willson; C D Funk; J W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

Review 2.  Regulation of osteoclast formation and function.

Authors:  L T Duong; G A Rodan
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 3.  PTH and PTHrP effects on the skeleton.

Authors:  A C Karaplis; D Goltzman
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

4.  MiR-30a attenuates osteoclastogenesis via targeting DC-STAMP-c-Fos-NFATc1 signaling.

Authors:  Yiran Yin; Lian Tang; Jieying Chen; Xiaobo Lu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

5.  Molecular mechanisms of the inhibitory effects of bovine lactoferrin on lipopolysaccharide-mediated osteoclastogenesis.

Authors:  Toshihiro Inubushi; Aki Kawazoe; Mutsumi Miyauchi; Yasusei Kudo; Min Ao; Atsushi Ishikado; Taketoshi Makino; Takashi Takata
Journal:  J Biol Chem       Date:  2012-05-16       Impact factor: 5.157

6.  Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter.

Authors:  Shanmugarajan Srinivasan; Masahiro Ito; Hiroshi Kajiya; L Lyndon Key; Theresa L Johnson-Pais; Sakamuri V Reddy
Journal:  Gene       Date:  2005-12-27       Impact factor: 3.688

Review 7.  Normal bone anatomy and physiology.

Authors:  Bart Clarke
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

8.  Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.

Authors:  Steven D Rhodes; Hao Yang; Ruizhi Dong; Keshav Menon; Yongzheng He; Zhaomin Li; Shi Chen; Karl W Staser; Li Jiang; Xiaohua Wu; Xianlin Yang; Xianghong Peng; Khalid S Mohammad; Theresa A Guise; Mingjiang Xu; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2015-05-21       Impact factor: 6.741

9.  NHA-oc/NHA2: a mitochondrial cation-proton antiporter selectively expressed in osteoclasts.

Authors:  R A Battaglino; L Pham; L R Morse; M Vokes; A Sharma; P R Odgren; M Yang; H Sasaki; P Stashenko
Journal:  Bone       Date:  2007-09-26       Impact factor: 4.398

10.  Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice.

Authors:  Mortaza Bonyadi; Stephen D Waldman; Danmei Liu; Jane E Aubin; Marc D Grynpas; William L Stanford
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.